CN105682741A - 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法 - Google Patents

使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法 Download PDF

Info

Publication number
CN105682741A
CN105682741A CN201480049491.7A CN201480049491A CN105682741A CN 105682741 A CN105682741 A CN 105682741A CN 201480049491 A CN201480049491 A CN 201480049491A CN 105682741 A CN105682741 A CN 105682741A
Authority
CN
China
Prior art keywords
endothelin
brain
irl
etb
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480049491.7A
Other languages
English (en)
Chinese (zh)
Inventor
A.古拉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midwestern University Glendale
Original Assignee
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University Glendale filed Critical Midwestern University Glendale
Priority to CN202110467579.2A priority Critical patent/CN113384701A/zh
Publication of CN105682741A publication Critical patent/CN105682741A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480049491.7A 2013-07-08 2014-07-08 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法 Pending CN105682741A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110467579.2A CN113384701A (zh) 2013-07-08 2014-07-08 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843702P 2013-07-08 2013-07-08
US61/843702 2013-07-08
US201361902935P 2013-11-12 2013-11-12
US61/902935 2013-11-12
PCT/US2014/045748 WO2015006324A2 (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110467579.2A Division CN113384701A (zh) 2013-07-08 2014-07-08 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法

Publications (1)

Publication Number Publication Date
CN105682741A true CN105682741A (zh) 2016-06-15

Family

ID=52280704

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480049491.7A Pending CN105682741A (zh) 2013-07-08 2014-07-08 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法
CN202110467579.2A Pending CN113384701A (zh) 2013-07-08 2014-07-08 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110467579.2A Pending CN113384701A (zh) 2013-07-08 2014-07-08 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法

Country Status (10)

Country Link
US (2) US10561704B2 (enExample)
EP (1) EP3019242B1 (enExample)
JP (2) JP6928450B2 (enExample)
CN (2) CN105682741A (enExample)
AU (1) AU2014287427B2 (enExample)
BR (1) BR112016000431A8 (enExample)
CA (2) CA2917325C (enExample)
ES (1) ES2825101T3 (enExample)
PL (1) PL3019242T3 (enExample)
WO (1) WO2015006324A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222663A1 (zh) * 2023-04-26 2024-10-31 拜西欧斯（北京）生物技术有限公司 多肽及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759791C (en) 2009-04-30 2018-04-10 Midwestern University Novel therapeutic treatments using centhaquin
BR112020022395A2 (pt) * 2018-05-03 2021-04-13 Midwestern University Alterações em receptores de endotelina em seguida a hemorragia e ressuscitação por centaquina
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043654A2 (en) * 2000-12-01 2002-06-06 Milos Pekny Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
CN101888851A (zh) * 2007-08-21 2010-11-17 美国中西部大学 使用内皮缩血管肽b受体激动剂治疗中风或脑血管意外的组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
US20040138121A1 (en) 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
CN101405020A (zh) 2006-03-23 2009-04-08 安米林药品公司 代谢疾病治疗中的内皮素和内皮素受体激动剂
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043654A2 (en) * 2000-12-01 2002-06-06 Milos Pekny Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
CN101888851A (zh) * 2007-08-21 2010-11-17 美国中西部大学 使用内皮缩血管肽b受体激动剂治疗中风或脑血管意外的组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TATSUROU YAGAMI ET AL.: "Effects of endothelin B receptor agonists on amyloid β protein (25–35)-induced neuronal cell death", 《BRAIN RESEARCH》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222663A1 (zh) * 2023-04-26 2024-10-31 拜西欧斯（北京）生物技术有限公司 多肽及其应用

Also Published As

Publication number Publication date
AU2014287427A1 (en) 2016-02-11
EP3019242A4 (en) 2017-01-25
JP6928450B2 (ja) 2021-09-01
US10561704B2 (en) 2020-02-18
WO2015006324A3 (en) 2015-11-05
US20200353031A1 (en) 2020-11-12
CN113384701A (zh) 2021-09-14
EP3019242B1 (en) 2020-08-19
PL3019242T3 (pl) 2021-02-08
JP7385924B2 (ja) 2023-11-24
CA2917325A1 (en) 2015-01-15
AU2014287427B2 (en) 2019-11-21
JP2016523969A (ja) 2016-08-12
ES2825101T3 (es) 2021-05-14
CA3171883A1 (en) 2015-01-15
JP2021020945A (ja) 2021-02-18
WO2015006324A2 (en) 2015-01-15
BR112016000431A8 (pt) 2018-01-23
US20160151450A1 (en) 2016-06-02
EP3019242A2 (en) 2016-05-18
CA2917325C (en) 2023-09-05
WO2015006324A8 (en) 2016-01-28
CA3171883C (en) 2024-03-05

Similar Documents

Publication Publication Date Title
JP7385924B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物
Xu et al. Activation of liver X receptors prevents emotional and cognitive dysfunction by suppressing microglial M1-polarization and restoring synaptic plasticity in the hippocampus of mice
US8716220B2 (en) Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US10555916B2 (en) NMDAR antagonist for the treatment of pervasive development disorders
Amin et al. Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period
Wu et al. Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition
US10772827B2 (en) Composition for treating apoplexy through nasal administration
Leung et al. Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex
US20210038589A1 (en) Uses, compositions and methods
JP2024519866A (ja) 神経学的疾患を治療するための方法及び組成物
Cantara et al. Opposite effects of beta amyloid on endothelial cell survival: role of fibroblast growth factor-2 (FGF-2)
WO2021010348A1 (ja) うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β１
US20230142111A1 (en) Compositions and methods for the treatment of pervasive development disorders
JP2022528748A (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
Situ Uncovering the Role of Connexin-43 in Blood Brain Barrier Dysfunction in Cerebral Amyloid Angiopathy
US11213494B2 (en) Compositions and methods for the treatment of pervasive development disorders
Zhou et al. Vitamin D3 alleviates AD-like pathology in APP/PS1 mice by inhibiting pyroptosis and neuroinflammation via DJ-1/PARK7
Schneider The effects of mTOR inhibition in ischemic stroke
KR20170085792A (ko) Tsp-1을 포함하는 알츠하이머병 예방 또는 치료용 조성물
Chen et al. P athway, European Journal of Pharmacology
Lee AdipoRon as a potential physical exercise-mimetic to ameliorate diabetes-associated cognitive impairment
Giarratana The effects of genetic polymorphisms on recovery after repeated mild traumatic brain injury in a mouse model and personalized treatment approaches
US20170202792A1 (en) Method for treating tau-associated diseases
Virachit Neurogenesis regulation in Parkinson's disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160615